Cargando…

Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy

Individualized therapies that are tailored to a patient's genetic composition will be of tremendous value for treatment of cancer. Recently, Kirsten ras (KRAS) status has emerged as a predictor of response to epidermal growth factor receptor (EGFR) targeted therapies. In this article, we will d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, David Z, Kumar, Vikas, Ma, Ying, Li, Kuiyuan, Kopetz, Scott
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686726/ https://www.ncbi.nlm.nih.gov/pubmed/19386128 http://dx.doi.org/10.1186/1756-8722-2-18

Ejemplares similares

Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics
por: Parseghian, Christine, et al.
Publicado: (2023)

KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy
por: Siddiqui, Ahmad D., et al.
Publicado: (2009)

KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies
por: Soulières, D., et al.
Publicado: (2010)

Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS
por: Kishiki, Tomokazu, et al.
Publicado: (2014)

KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition
por: Rouleau, E, et al.
Publicado: (2008)

Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2016)

Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer
por: Fiore, F Di, et al.
Publicado: (2008)

Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
por: Gattenlöhner, S., et al.
Publicado: (2009)

Colorectal Cancer Patients with Low Abundance of KRAS Mutation May Benefit from EGFR Antibody Therapy
por: Yu, Shaorong, et al.
Publicado: (2013)

KRAS mutation in colorectal cancer metastases after adjuvant FOLFOX for the primary
por: Vauthey, J-N, et al.
Publicado: (2012)

A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer
por: Balko, Justin M, et al.
Publicado: (2009)

EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy
por: Uhlyarik, Andrea, et al.
Publicado: (2020)

Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer
por: Fakih, Marwan, et al.
Publicado: (2022)

Targeting the untargetable KRAS in cancer therapy
por: Liu, Pingyu, et al.
Publicado: (2019)

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response
por: Liu, X., et al.
Publicado: (2015)

EGFR-Based Targeted Therapy for Colorectal Cancer—Promises and Challenges
por: Janani, Balakarthikeyan, et al.
Publicado: (2022)

HER2 expression as a potential marker for response to therapy targeted to the EGFR
por: Emlet, D R, et al.
Publicado: (2006)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

Oleic acid-induced metastasis of KRAS/p53-mutant colorectal cancer relies on concurrent KRAS activation and IL-8 expression bypassing EGFR activation
por: Shen, Chih-Jie, et al.
Publicado: (2023)

The involvement of Kras gene 3′-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis
por: Ying, Hou-Qun, et al.
Publicado: (2014)

Oncogenic Kras drives invasion and maintains metastases in colorectal cancer
por: Boutin, Adam T., et al.
Publicado: (2017)

Current Approaches for Predicting a Lack of Response to Anti-EGFR Therapy in KRAS Wild-Type Patients
por: Er, Tze-Kiong, et al.
Publicado: (2014)

Therapeutic Targets of KRAS in Colorectal Cancer
por: Rahman, Shafia, et al.
Publicado: (2021)

A mechanism for the response of KRAS(G13D) expressing colorectal cancers to EGFR inhibitors
por: McFall, Thomas, et al.
Publicado: (2020)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer
por: Pichler, M, et al.
Publicado: (2012)

Molecular Characterization of Acquired Resistance to KRAS(G12C)–EGFR Inhibition in Colorectal Cancer
por: Yaeger, Rona, et al.
Publicado: (2023)

Optimization of routine KRAS mutation PCR-based testing procedure for rational individualized first-line-targeted therapy selection in metastatic colorectal cancer
por: Chretien, Anne-Sophie, et al.
Publicado: (2013)

The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer
por: Huang, Ching-Wen, et al.
Publicado: (2013)

The Frequency of EGFR and KRAS Mutations in the Turkish Population with Non-small Cell Lung Cancer and their Response to Erlotinib Therapy
por: Demiray, A, et al.
Publicado: (2018)

Association between KRAS mutation and lung metastasis in advanced colorectal cancer
por: Pereira, A A L, et al.
Publicado: (2015)

A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab
por: Lee, Sang-Kyu, et al.
Publicado: (2018)

EGFR-Targeted TRAIL and a Smac Mimetic Synergize to Overcome Apoptosis Resistance in KRAS Mutant Colorectal Cancer Cells
por: Möller, Yvonne, et al.
Publicado: (2014)

EGFR-Targeted Photodynamic Therapy
por: Ulfo, Luca, et al.
Publicado: (2022)

Combinatorial approaches for mitigating resistance to KRAS-targeted therapies
por: Warren, Hannah R., et al.
Publicado: (2022)

Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
por: Hasbullah, Hidayati Husainy, et al.
Publicado: (2021)

Id-1: Regulator of EGFR and VEGF and potential target for colorectal cancer therapy
por: Meteoglu, Ibrahim, et al.
Publicado: (2008)

CRE: a cost effective and rapid approach for PCR-mediated concatenation of KRAS and EGFR exons: Rapid way to detect EGFR and KRAS mutations
por: Ramteke, Manoj P., et al.
Publicado: (2016)

KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
por: Lopez-Crapez, E, et al.
Publicado: (2010)

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models
por: Lee, Michael S., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_jr2r601vscfh6atjejq07p3i2g